Business Operations:

Sector: Healthcare
Industry: Medical Devices

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Revenue projections:

With ZBH's revenue expected to be lower than the previous year, investors may become cautious. Declining revenues often negatively impact the bottom line, reducing profitability and raising concerns among investors about the company's ability to maintain strong financial performance moving forward.

Financial Ratios:

currentRatio	1.691000
forwardPE	10.493417
debtToEquity	60.175000
earningsGrowth	0.338000
revenueGrowth	0.048000
grossMargins	0.695240
operatingMargins	0.179600
trailingEps	4.110000
forwardEps	9.051390

Zimmer Biomet Holdings, Inc.'s current ratio, being 1.691, demonstrates that the company has the liquidity necessary to service its short-term debt. With strong cash reserves and current assets, Zimmer Biomet Holdings, Inc. is well-equipped to meet its immediate financial obligations without any difficulties.
Zimmer Biomet Holdings, Inc.'s Forward PE is in a favorable range, suggesting the stock is reasonably priced relative to its earnings. This indicates the stock is not overpriced, providing room for potential growth and making it an attractive option for investors looking for solid value and future upside.
ZBH's forward EPS being higher than its trailing EPS signals anticipated growth in profitability for the current financial year. This suggests that ZBH is on track to improve its earnings, outpacing the previous year's performance and reflecting positive market expectations.

Price projections:

Price projections for Zimmer Biomet Holdings, Inc. have been gradually lowered, signaling reduced optimism among analysts. This downward adjustment suggests that the company may face challenges in meeting previous growth expectations.

Insider Transactions:

ZBH stock was sold in 8 transactions, with market price at 96.61740493774414.During the period under consideration, there were no sell transactions.The recent buying activity at current Zimmer Biomet Holdings, Inc. price levels exceeds selling, suggesting a potential positive outlook. Investors may see this trend as an indicator that the stock is likely to perform well, reflecting growing confidence.

Recommendation changes over time:

Analysts have been favoring Zimmer Biomet Holdings, Inc. with a buy bias recently, signaling a promising investment opportunity. This optimistic outlook may attract more investors, positioning Zimmer Biomet Holdings, Inc. as a desirable option for those seeking to invest their money in a stable, profitable company with strong growth potential.